Surface chemical and physical modification in stent technology for the treatment of coronary artery disease

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 100 B, Issue 7, 2012, Pages 1989-2014

  Nazneen, Feroze ^a   Herzog, Grégoire ^b   Arrigan, Damien W M ^c   Caplice, Noel ^d   Benvenuto, Pasquale ^e   Galvin, Paul ^a   Thompson, Michael ^e  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Laboratoire de Chimie Physique et Microbiologie pour l'Environnement   (France)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

biocompatibility; cardiovascular; cell material interactions; stents; surface modification

Indexed keywords

BALLOON ANGIOPLASTY; CARDIOVASCULAR; CELL-MATERIAL INTERACTION; CORONARY ARTERY DISEASE; FUTURE PERSPECTIVES; IN-VITRO; NANOSTRUCTURED SURFACE; PATHOPHYSIOLOGY; PHYSICAL MODIFICATIONS; RESEARCH EFFORTS; SMOOTH MUSCLES; STENT IMPLANTATION; SURFACE CHEMICALS; VASCULAR CELLS;

BIOCOMPATIBILITY; CELL CULTURE; DISEASES; STENTS; SURFACE TREATMENT; SURFACES;

CHEMICAL MODIFICATION;

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; EVEROLIMUS; INORGANIC COMPOUND; ORGANIC COMPOUND; PACLITAXEL; POLYMER; RAPAMYCIN; TACROLIMUS;

ANTICOAGULANT THERAPY; ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; BALLOON DILATATION; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOMECHANICS; BLOOD VESSEL FUNCTION; BLOOD VESSEL INJURY; CELL FUNCTION; CHEMICAL MODIFICATION; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIUM CELL; FIBROBLAST; HEALING; HUMAN; IN VITRO STUDY; INFLAMMATION; MATERIAL COATING; NANOFABRICATION; NEOINTIMA; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL MODIFICATION; POROSITY; REVIEW; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; SURFACE PROPERTY; THROMBOSIS PREVENTION;

ANGIOPLASTY, BALLOON, CORONARY; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY DISEASE; HUMANS; NANOSTRUCTURES; STENTS; SURFACE PROPERTIES;

EID: 84866002230     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32772     Document Type: Review

References (311)

1. Mackay J, Mensah G,. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004. pp 84-91.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Liu LS, Investigators IS,. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-952.
3. Haller JD, Olearchyk AS,. Cardiology's 10 greatest discoveries. Tex Heart Inst J 2002; 29: 342-344.
4. Choi D, Hwang KC, Lee KY, Kim YH,. Ischemic heart diseases: Current treatments and future. J Controlled Release 2009; 140: 194-202.
5. Gruntzig A,. Trans-luminal dilatation of coronary-artery stenosis. Lancet 1978; 1: 263.
6. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L,. Intravascular stents to prevent occlusion and restenosis after trans-luminal angioplasty. N Engl J Med 1987; 316: 701-706.
7. Klein LW, Rosenblum J,. Restenosis after successful percutaneous transluminal coronary angioplasty. Prog Cardiovasc Dis 1990; 32: 365-382.
8. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH,. Syndromes of accelerated atherosclerosis-Role of vascular injury and smooth-muscle cell-proliferation. J Am Coll Cardiol 1990; 15: 1667-1687.
9. Rensing BJ, Hermans WRM, Beatt KJ, Laarman GJ, Suryapranata H, Vandenbrand M, Defeyter PJ, Serruys PW,. Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 66: 1039-1044.
10. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H,. Restenosis after successful percutaneous trans-luminal coronary angioplasty-Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12: 616-623.
11. Lowe H, Oesterle SN, Khachigian LM,. Coronary in-stent restenosis: Current status and future strategies. J Am Coll Cardiol 2002; 39: 183-193.
12. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S,. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary-artery disease. N Engl J Med 1994; 331: 496-501.
13. Serruys PW, Dejaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, Vandenheuvel P, Delcan J, Morel MA,. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary-artery disease. N Engl J Med 1994; 331: 489-495.
14. Virmani R, Farb A,. Pathology of in-stent restenosis. Curr Opin Lipidol 1999; 10: 499-506.
15. Morice M, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R,. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
16. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE,. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
17. Grube E, Buellesfeld L,. Initial experience with paclitaxel-coated stents. J Interv Cardiol 2002; 15: 471-475.
18. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ,. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement results from the PREMIER registry. Circulation 2006; 113: 2803-2809.
19. Ong ATL, Serruys PW,. Drug-Eluting Stents-Current Issues. Orlando, FL: Texas Heart Inst; 2005. pp 372-377.
20. McFadden EP, Stabile E, Regar E, Cheneau E, Ong ATL, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW,. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
21. Ong ATL, McFadden EP, Regar E, de Jaegere PPT, van Domburg RT, Serruys PW,. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-2092.
22. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue ZY, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R,. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113: 1108-1113.
23. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A,. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA-J Am Med Assoc 2005; 293: 2126-2130.
24. Do drug-eluting stents increase deaths? Accessed June 9, 2008 from European Society of Cardiology, ESC Event News, World Congress of Cardiology. Available at: http://www.escardio.org/vpo/News/events/wcc-drugelutingstents- events.htm.
25. Boston scientific confirms long-term clotting risk of drug-eluting stents. Accessed June 9, 2008 from Angioplasty.org website. Accessed date June 9, 2008. Available at: http://www.ptca.org/news/2006/0907.html.
26. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD,. Hypersensitivity cases associated with drug-eluting coronary stents-A review of available cases from the research on adverse drug events and reports (RADAR) project. Orlando, FL: Elsevier Science Inc; 2005. pp 175-181.
27. Stoeckel D, Bonsignore C, Duda S,. A survey of stent designs. Minim Invasive Ther Allied Tech 2002; 11: 137-147.
28. Borovetz HS, Burke JF, Chang TMS, Colas A, Cranin AN, Curtis J, Gemmell CH, Griffith BP, Hallab NJ, Heller J,. Application of Materials in Medicine, Biology and Artificial Organs. Elsevier Academic Press, California, USA 2004. pp 455-707.
29. Mani G, Feldman MD, Patel D, Agrawal CM,. Coronary stents: A materials perspective. Biomaterials 2007; 28: 1689-1710.
30. Schatz RA,. A view of vascular stents. Circulation 1989; 79: 445-457.
31. Zahora J, Bezrouk A, Hanus J,. Models of stents-Comparison and applications. Physiol Res 2007; 56: S115-S121.
32. Kathuria YP,. The potential of biocompatible metallic stents and preventing restenosis. Mater Sci Eng A-Struct Mater Prop Microstruct Process 2006; 417: 40-48.
33. Konig A, Schiele TM, Rieber J, Theisen K, Mudra H, Klauss V,. Stent design-related coronary artery remodeling and patterns of neointima formation following self-expanding and balloon-expandable stent implantation. Cathet Cardiovasc Interv 2002; 56: 478-486.
34. Park J, Bronzino J,. Biomaterials: Principles and Applications. Boca Raton, FL: CRC Press; 2003.
35. Ratner B,. Biomaterials Science: An Introduction to Materials in Medicine. Elsevier Academic Press, California, USA; 2004.
36. Thierry B, Merhi Y, Bilodeau L, Trepanier C, Tabrizian M,. Nitinol versus stainless steel stents: Acute thrombogenicity study in an ex vivo porcine model. Biomaterials 2002; 23: 2997-3005.
37. Cardarelli F,. Ferrous Metals and Their Alloys. Springer, London; 2008. pp 59-157.
38. Shabalovskaya SA,. On the nature of the biocompatibility and on medical applications of NiTi shape memory and superelastic alloys. Biomed Mater Eng 1996; 6: 267-289.
39. BergerGorbet M, Broxup B, Rivard C, Yahia LH,. Biocompatibility testing of NiTi screws using immunohistochemistry on sections containing metallic implants. J Biomed Mater Res 1996; 32: 243-248.
40. Maitz MF, Shevchenko N,. Plasma-immersion ion-implanted nitinol surface with depressed nickel concentration for implants in blood. J Biomed Mater Res A 2006; 76A: 356-365.
41. O'Brien B, Carroll WM, Kelly MJ,. Passivation of nitinol wire for vascular implants-A demonstration of the benefits. Biomaterials 2002; 23: 1739-1748.
42. Trepanier C, Tabrizian M, Yahia L, Bilodeau L, Piron DL,. Effect of modification of oxide layer on NiTi stent corrosion resistance. J Biomed Mater Res 1998; 43: 433-440.
43. Mazumder MM, De S, Trigwell S, Ali N, Mazumder MK, Mehta JL,. Corrosion resistance of polyurethane-coated Nitinol cardiovascular stents. J Biomater Sci Polym Ed 2003; 14: 1351-1362.
44. Starosvetsky D, Gotman I,. Corrosion behavior of titanium nitride coated Ni-Ti shape memory surgical alloy. Biomaterials 2001; 22: 1853-1859.
45. Shih CC, Lin SJ, Chung KH, Chen YL, Su YY,. Increased corrosion resistance of stent materials by converting current surface film of polycrystalline oxide into amorphous oxide. J Biomed Mater Res 2000; 52: 323-332.
46. Butany J, Carmichael K, Leong SW, Collins MJ,. Coronary artery stents: Identification and evaluation. J Clin Pathol 2005; 58: 795-804.
47. Burt HM, Hunter WL,. Drug-eluting stents: A multidisciplinary success story. Adv Drug Delivery Rev 2006; 58: 350-357.
48. McLean D, Eiger N,. Stent design: Implications for restenosis. Rev Cardiovasc Med 2002; 3: S16.
49. Gurbel P, Callahan K, Malinin A, Serebruany V, Gillis J,. Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. J Invasive Cardiol 2002; 14: 584-589.
50. Kastrati A, Mehilli J, Dirschinger J, Pache J, Ulm K, Schühlen H, Seyfarth M, Schmitt C, Blasini R, Neumann F,. Restenosis after coronary placement of various stent types. Am J Cardiol 2001; 87: 34-39.
51. Yoshitomi Y, Kojima S, Yano M, Sugi T, Matsumoto Y, Saotome M, Tanaka K, Endo M, Kuramochi M,. Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. Am Heart J 2001; 142: 445-451.
52. Rogers C, Edelman E,. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995; 91: 2995-3001.
53. Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F, Sattelberger U, Dirschinger J, Schomig A,. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: Results from the ISAR-STEREO trial. Am Heart J 2003; 146: 882-886.
54. Lau K, Johan A, Sigwart U, Hung J,. A stent is not just a stent: Stent construction and design do matter in its clinical performance. Singapore Med J 2004; 45: 305-312.
55. Thuesen L, Andersen H, Krusell L, Botker H, Jorgensen E, Kelbaek H, Kristensen S,. Randomized comparison of the coil-design Crossflex and the tubular NIR stent. Cathet Cardiovasc Interv 2003; 59: 8-12.
56. Pache J, Kastrati A, Mehilli J, Schühlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann F, Sattelberger U, Schmitt C,. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41: 1283-1288.
57. Hoffmann R, Mintz GS, Haager PK, Bozoglu T, Grube E, Gross M, Beythien C, Mudra H, vom Dahl J, Hanrath P,. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol 2002; 89: 1360-1364.
58. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, Sgura F, Corvaja N, Albiero R, Stankovic G, Toutoutzas C, Bonizzoni E, Di Mario C, Colombo A,. In-stent restenosis in small coronary arteries -impact of strut thickness. J Am Coll Cardiol 2002; 40: 403-409.
59. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann F, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A,. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816-2821.
60. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A,. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J 2005; 26: 1262-1268.
61. Bennett MR,. In-stent stenosis: Pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218-224.
62. Karthikeyan G, Bhargava B,. Prevention of restenosis after coronary angioplasty. Curr Opin Cardiol 2004; 19: 500-509.
63. Rozenman Y, Gilon D, Welber S, Sapoznikov D, Gotsman MS,. Clinical and angiographic predictors of immediate recoil after successful coronary angioplasty and relation to late restenosis. Am J Cardiol 1993; 72: 1020-1025.
64. Rodriguez AE, Palacios IF, Fernandez MA, Larribau M, Giraudo M, Ambrose JA,. Time-course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995; 76: 1131-1134.
65. White C,. Drug-Eluting Stents: Advanced Applications for the Management of Coronary Disease. Taylor & Francis, Texas, USA; 2005.
66. Liu MW, Roubin GS, King SB III,. Restenosis following coronary angioplasty potential biological determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-1387.
67. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu HS, Leon MB,. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-230.
68. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE,. Neointimal tissue response at sites of coronary stenting in humans-Macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233.
69. Ott I, Neumann FJ, Kenngott S, Gawaz M, Schomig A,. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. Am J Cardiol 1998; 82: 938-942.
70. Smith-Norowitz TA, Shani J, Weiser W, Schulhoff N, Norowitz K, Lichstein E, Mokhtarian F,. Lymphocyte activation in angina pectoris. Clin Immunol 1999; 93: 168-175.
71. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR,. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 2002; 105: 633-638.
72. Cirillo P, Golino P, Ragni M, Battaglia C, Pacifico F, Formisano S, Buono C, Condorelli M,. Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovasc Res 1999; 43: 210-218.
73. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK,. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000; 102: 1697-1702.
74. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S,. Anti-monocyte chemoattractant protein-1 monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 1999; 84: 306-314.
75. Schwartz R, Henry T,. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med 2002; 3: S4.
76. Salam AM, Al Suwaidi J, Holmes DR,. Drug-eluting coronary stents. Curr Probl Cardiol 2006; 31: 8-119.
77. Clowes AW, Schwartz SM,. Significance of quiescent smooth-muscle migration in the injured rat carotid-artery. Circ Res 1985; 56: 139-145.
78. Schwartz RS, Henry TD,. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med 2002; 3: S4.
79. Wong A, Chan C,. Drug-eluting stents: The end of restenosis? Ann Acad Med Singapore 2004; 33: 423-431.
80. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R,. Pathology of drug-eluting stents in humans-Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
81. Daemen J, Serruys PW,. Drug-eluting stent update 2007 part I: A survey of current and future generation drug-eluting stents: Meaningful advances or more of the same? Circulation 2007; 116: 316-328.
82. Unterberg C, Sandrock D, Nebendahl K, Buchwald AB,. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol 1995; 26: 1747-1754.
83. Schwartz RS, Holder DJ, Holmes DR, Veinot JP, Camrud AR, Jorgenson MA, Johnson RG,. Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor-results in a porcine model. Circulation 1996; 93: 1542-1548.
84. Kastrati A, Schuhlen H, Hausleiter J, Walter H, ZitzmannRoth E, Hadamitzky M, Elezi S, Ulm K, Dirschinger J, Neumann FJ, Schomig A,. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy-Six-month angiographic follow-up of the intracoronary stenting and antithrombotic regimen (ISAR) trial. Circulation 1997; 96: 462-467.
85. Ellis S, Effron M, Gold H, Leon M, Popma J, Serruys P, Colombo A, Cohen N, Juran N, Werner W,. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999; 100: 799-806.
86. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N,. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999; 100: 21-26.
87. Lee CW, Chae JK, Lim HY, Hong MK, Kim JJ, Park SW, Park SJ,. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 1999; 138: 60-63.
88. Meurice T, Bauters C, Hermant X, Codron V, VanBelle E, Mc Fadden EP, Lablanche JM, Bertrand ME, Amouyel P,. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): A randomised, double-blind, placebo-controlled trial. Lancet 2001; 357: 1321-1324.
89. Serruys P, Foley D, Pieper M, Kleijne J,. The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Eur Heart J 2001; 22: 1938.
90. Babapulle MN, Eisenberg MJ,. Coated stents for the prevention of restenosis: Part I. Circulation 2002; 106: 2734-2740.
91. Depalma VA, Baier RE, Gott VL, Ford JW, Furuse A,. Investigation of 3-surface properties of several metals and their relation to blood compatibility. J Biomed Mater Res 1972; 6: 37-75.
92. Hecker JF, Scandrett LA,. Roughness and thrombogenecity of the outer surfaces of intravascular catheters. J Biomed Mater Res 1985; 19: 381-395.
93. Trigwell S, Hayden RD, Nelson KF, Selvaduray G,. Effects of surface treatment on the surface chemistry of NiTi alloy for biomedical applications. Surf Interface Anal 1998; 26: 483-489.
94. Eliaz N, Nissan O,. Innovative processes for electropolishing of medical devices made of stainless steels. J Biomed Mater Res A 2007; 83A: 546-557.
95. William G., Wood AHC, ASM Surface Treating and Coating Division Council. Metals Handbook: Surface Cleaning, Finishing and Coating, Vol. 5. Ohio: American Chemical Society for Metals; 1982. p 715.
96. Haidopoulos M, Turgeon S, Sarra-Bournet C, Laroche G, Mantovani D,. Development of an optimized electrochemical process for subsequent coating of 316 stainless steel for stent applications. J Mater Sci Mater Med 2006; 17: 647-657.
97. Zhao H, Van Humbeeck J, Sohier J, De Scheerder I,. Electrochemical polishing of 316L stainless steel slotted tube coronary stents. J Mater Sci Mater Med 2002; 13: 911-916.
98. Raval A, Choubey A, Engineer C, Kothwala D,. Development and assessment of 316LVM cardiovascular stents. Mater Sci Eng A-Struct Mater Prop Microstruct Process 2004; 386: 331-343.
99. Wang K,. Biocompatibilisation of Coronary Artery Stents. Leuven University Press Belgium; 1997.
100. Sheth S, Litvack F, Fishbein MC, Forrester JS, Eigler NL,. Reduced thrombogenicity of polished and unpolished nitinol vs. stainless steel slotted-tube stents in a pig coronary artery model. JACC 1996:Abstracts-Poster: 197A.
101. De Scheerder I, Verbeken E, Van Humbeeck J,. Metallic surface modification. Semin Interv Cardiol 1998; 3: 139-144.
102. De Scheerder I, Sohier J, Verbeken E, Froyen L, Van Humbeeck J,. Biocompatibility of coronary stent materials: Effect of electrochemical polishing. Materialwissenschaft Und Werkstofftechnik 2001; 32: 142-148.
103. De Scheerder I, Wang K, Sohier J, Verbeken E, Zhou XR, Frooyen L, Van Humbeeck J, Van de Werf F,. Metallic surface treatment using electrochemical polishing decreases thrombogenicity and neointimal hyperplasia after coronary stent implantation in a porcine model. J Am Coll Cardiol 1998; 31: 277A.
104. Hehrlein C, Zimmermann M, Metz J, Ensinger W, Kubler W,. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron Artery Dis 1995; 6: 581-586.
105. Liu CL, Chu PK, Lin GQ, Qi M,. Anti-corrosion characteristics of nitride-coated AISI 316L stainless steel coronary stents. Surf Coating Tech 2006; 201: 2802-2806.
106. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP,. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-2295.
107. Chen MC, Liang HF, Chiu YL, Chang Y, Wei HJ, Sung HW,. A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus. J Controlled Release 2005; 108: 178-189.
108. Huang N, Leng Y, Yang P, Chen J, Sun H, Wang J, Wan G, Zhao A, Ding P,. Surface modification of coronary artery stent by Ti-O/Ti-N complex film coating prepared with plasma immersion ion implantation and deposition. Nucl Instrum Meth Phys Res Sect B 2006; 242: 18-21.
109. Nguyen K, Su SH, Zilberman M, Bohluli P, Frenkel P, Tang L, Eberhart R, Timmons R,. Biomaterials and Stent Technology. Tissue Engineering and Novel Delivery Systems. CRC Press, Texas, USA 2004. p 107.
110. Hara H, Nakamura M, Palmaz JC, Schwartz RS,. Role of stent design and coatings on restenosis and thrombosis. Adv Drug Delivery Rev 2006; 58: 377-386.
111. Duda SH, Poerner TC, Wiesinger B, Rundback JH, Tepe G, Wiskirchen J, Haase KK,. Drug-eluting stents: Potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol 2003; 14: 291-301.
112. Edelman E, Seifert P, Groothuis A, Morss A, Bornstein D, Rogers C,. Gold-coated NIR stents in porcine coronary arteries. Circulation 2001; 103: 429-434.
113. Harding S, McKenna C, Flapan A, Boon N,. Long-term clinical safety and efficacy of NIROYAL vs. NIR intracoronary stent. Cathet Cardiovasc Diagn 2001; 54: 141-145.
114. Cremonesi A, Benit E, Carlier M, Colombo A, Piva R, Probst P, Wirtzfeld A, Pico-Bourdonnec C, Corcos T,. Multicenter registry to evaluate the efficacy of the NIROYAL™ stent in de novo or restenotic coronary stenosis. J Invasive Cardiol 2000; 12: 225-235.
115. Kastrati A, Schomig A, Dirschinger J, Mehilli J, von Welser N, Pache J, Schuhlen H, Schilling T, Schmitt C, Neumann F,. Increased risk of restenosis after placement of gold-coated stents: Results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 2000; 101: 2478.
116. Hofma S, Van Beusekom H, Serruys P, van Der Giessen W,. Recent developments in coated stents. Curr Interv Cardiol Rep 2001; 3: 28.
117. vom Dahl J, Haager P, Grube E, Gross M, Beythien C, Kromer E, Cattelaens N, Hamm C, Hoffmann R, Reineke T,. Effects of gold coating of coronary stents on neointimal proliferation following stent implantation* 1. Am J Cardiol 2002; 89: 801-805.
118. Danzi G, Capuano C, Sesana M, Di Blasi A, Predolini S, Antoniucci D,. Patterns of in-stent restenosis after placement of NIR gold-coated stents in unselected patients. Cathet Cardiovasc Interv 2002; 55: 157-162.
119. Monnink S, Van Boven A, Peels H, Tigchelaar I, De Kam P, Crijns H, Van Oeveren W,. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. J Investig Med 1999; 47: 304-310.
120. Bolz A, Schaldach M,. Artificial-heart valves-Improved blood compatibility by Pecvd a-Sic-H coating. Artif Organs 1990; 14: 260-269.
121. Harder C, Rzany A, Schaldach M,. Coating of vascular stents with antithrombogenic amorphous silicon carbide. Prog Biomed Res 1999; 4: 71-77.
122. Heublein B, Pethig K, Elsayed A,. Silicon carbide coating-A semiconducting hybrid design of coronary stents-A feasibility study. J Invasive Cardiol 1998; 10: 255-262.
123. Kalnins U, Erglis A, Dinne I, Kumsars I, Jegere S,. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease. Med Sci Monitor: Int Med J Exp Clin Res 2002; 8: PI16-PI20.
124. Unverdorben M, Sippel B, Degenhardt R, Sattler K, Fries R, Abt B, Wagner E, Koehler H, Daemgen G, Scholz M,. Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: The Tenax versus Nir stent study's long-term outcome. Am Heart J 2003; 145: 17.
125. Tanajura L, Abizaid A, Feres F, Pinto I, Mattos L, Staico R,. Randomized intravascular ultrasound comparison between patients that underwent amorphous hydrogenated silicon-carbide coated stent deployment versus uncoated stents. J Am Coll Cardiol 2003; 41: 58A.
126. Gutensohn K, Beythien C, Bau J, Fenner T, Grewe P, Koester R, Padmanaban K, Kuehnl P,. In vitro analyses of diamond-like carbon coated stents: Reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 2000; 99: 577-585.
127. Airoldi F, Colombo A, Tavano D, Stankovic G, Klugmann S, Paolillo V, Bonizzoni E, Briguori C, Carlino M, Montorfano M,. Comparison of diamond-like carbon-coated stents versus uncoated stainless steel stents in coronary artery disease. Am J Cardiol 2004; 93: 474-477.
128. Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Bolognese L, Santoro G, Cerisano G,. Clinical and angiographic outcomes following elective implantation of the carbostent in patients at high risk of restenosis and target vessel failure. Cathet Cardiovasc Diagn 2001; 54: 420-426.
129. Colombo A, Airoldi F,. Passive coating: The dream does not come true. J Invasive Cardiol 2003; 15: 566-567.
130. Seliger C, McCall R, Wolf WP, Resch A, Alt EU,. Influence of a rough, ceramic-like stent surface made of iridium oxide on neointimal structure and thickening in an animal study: 1 and 6 month data. Circulation 2000; 102: 733.
131. Di Mario C, Grube E, Nisanci Y, Reifart N, Colombo A, Rodermann J, Muller R, Umman S, Liistro F, Montorfano M, Alt E,. MOONLIGHT: A controlled registry of an iridium oxide-coated stent with angiographic follow-up. Int J Cardiol 2004; 95: 329-331.
132. Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G, Leskosek B, Meier B, Hess OM,. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001; 104: 928-933.
133. Windecker S, Simon RD, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T, Wenaweser P, Togni M, Tuller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM,. Randomized comparison of a titanium-nitride-oxide coated stent with a stainless steel Stent for coronary revascularization. Circulation 2005; 111: 2617-2622.
134. Karjalainen P, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietilä M, Sia J, Tuomainen P, Nyman K, Airaksinen K,. Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction. Ann Med 2009; 41: 599-607.
135. Karjalainen PP, Annala AP, Ylitalo A, Vahlberg T, Airaksinen KEJ,. Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. Int J Cardiol 2010; 144: 42-46.
136. Kraitzer A, Kloog Y, Zilberman M,. Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater 2008; 85B: 583-603.
137. van der Giessen W, Lincoff A, Schwartz R, van Beusekom H, Serruys P, Holmes D, Ellis S, Topol E,. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697.
138. Shikanov A, Vaisman B, Krasko MY, Nyska A, Domb AJ,. Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel: In vitro release and in vivo toxicity. J Biomed Mater Res A 2004; 69A: 47-54.
139. Lee SH, Szinai I, Carpenter K, Katsarava R, Jokhadze G, Chu CC, Huang YM, Verbeken E, Bramwell O, De Scheerder I, Hong MK,. In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer. Coron Artery Dis 2002; 13: 237-241.
140. Grenadier E, Roguin A, Hertz I, Peled B, Boulos M, Nikolsky E, Amikam S, Kerner A, Cohen S, Beyar R,. Stenting very small coronary narrowings (< 2 mm) using the biocompatible phosphorylcholine-coated coronary stent. Cathet Cardiovasc Interv 2002; 55: 303-308.
141. Galli M, Bartorelli A, Bedogni F, DeCesare N, Klugmann S, Maiello T, Miccoli F, Moccetti T, Onofri M, Paolillo V, Pirisi R, Presbitero T, Sganzerla P, Viecca M, Zerboni S, Lanteri G,. Italian BiodivYsio open registry (BiodivYsio PC-coated stent): Study of clinical outcomes of the implant of a PC-coated coronary stent. J Invasive Cardiol 2000; 12: 452-458.
142. Zheng H, Barragan P, Corcos T, Simeoni J, Favereau X, Roquebert P, Guerin Y, Sainsous J,. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J Invasive Cardiol 1999; 11: 608-614.
143. Moses J, Buller C, Nukta E, Aluka A, Barbeau G, Popma J, Moussa I, New G, Fiet F,. The first clinical trial comparing a coated versus a non-coated coronary stent: The Biocompatibles BiodivYsio™ stent in randomised control trial (distinct). Circulation 2000; 102: 11664.
144. Verheye S, Markou CP, Salame MY, Wan B, King SB, Robinson KA, Chronos NAF, Hanson SR,. Reduced thrombus formation by hyaluronic acid coating of endovascular devices. Atherioscler Thromb Vasc Biol 2000; 20: 1168-1172.
145. Radosevich M, Goubran HA, Burnouf T,. Fibrin sealant: Scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997; 72: 133-143.
146. Holmes DR, Camrud AR, Jorgenson MA, Edwards WD, Schwartz RS,. Polymeric stenting in the porcine coronary-artery model-Differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994; 24: 525-531.
147. McKenna CJ, Camrud AR, Sangiorgi G, Kwon HM, Edwards WD, Holmes DR, Schwartz RS,. Fibrin-film stenting in a porcine coronary injury model: Efficacy and safety compared with uncoated stents. J Am Coll Cardiol 1998; 31: 1434-1438.
148. Byer A, Peters S, Settepani F, Pagliaro M, Galletti G,. Fibrin sealant coated stents compared with non-coated stents in a porcine carotid artery model-Preliminary study report. J Cardiovasc Surg (Torino) 2001; 42: 543-549.
149. DeScheerder I, Wang K, Wilczek K, Meuleman D, VanAmsterdam R, Vogel G, Piessens J, VandeWerf F,. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997; 95: 1549-1553.
150. Hardhammar PA, vanBeusekom HMM, Emanuelsson HU, Hofma SH, Albertsson PA, Verdouw PD, Boersma E, Serruys PW, vanderGiessen WJ,. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93: 423-430.
151. Ahn YK, Jeong MH, Kim JW, Kim SH, Cho JH, Cho JG, Park CS, Juhng SW, Park JC, Kang JC,. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Cathet Cardiovasc Interv 1999; 48: 324-330.
152. Matsumoto Y, Shimokawa H, Morishige K, Eto Y, Takeshita A,. Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries. J Cardiovasc Pharmacol 2002; 39: 513-522.
153. Semiz E, Ermis C, Yalçinkaya S, Sancaktar O, Deger N,. Comparison of initial efficacy and long-term follow-up of heparin-coated Jostent with conventional NIR stent. Jpn Heart J 2003; 44: 889-898.
154. Haude M, Konorza T, Kalnins U, Erglis A, Saunamaki K, Glogar H, Grube E, Gil R, Serra A, Richardt H,. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003; 107: 1265-1270.
155. Wohrle J, Al-Khayer E, Grotzinger U, Schindler C, Kochs M, Hombach V, Hoher M,. Comparison of the heparin coated vs the uncoated Jostent (R)-No influence on restenosis or clinical outcome. Eur Heart J 2001; 22: 1808-1816.
156. Pendyala L, Jabara R, Shinke T, Chronos N, Robinson K, Li J, Hou D,. Drug-eluting stents: Present and future. Cardiovasc Hematol Agents Med Chem 2008; 6: 105-115.
157. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD,. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? Circulation 2004; 109: 701-705.
158. Virmani R, Farb A, Guagliumi G, Kolodgie FD,. Drug-eluting stents: Caution and concerns for long-term outcome. Coron Artery Dis 2004; 15: 313-318.
159. Virmani R, Kolodgie F, Farb A,. Drug-eluting stents: Are they really safe? Am Heart Hosp J 2004; 2: 85-88.
160. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R,. Vascular responses to drug eluting stents. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
161. Harper RW,. Drug-eluting coronary stents-A note of caution. Med J Aust 2007; 186: 253-255.
162. Wieneke H, Dirsch O, Sawitowski T, Gu YL, Brauer H, Dahmen U, Fischer A, Wnendt S, Erbel R,. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Cathet Cardiovasc Interv 2003; 60: 399-407.
163. Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A, Haberstroh J, Wnendt S, Virmani R, Hehrlein C,. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Cathet Cardiovasc Interv 2005; 64: 85-90.
164. Tsujino I, Ako J, Honda Y, Fitzgerald PJ,. Drug delivery via nano-, micro and macroporous coronary stent surfaces. Expert Opin Drug Delivery 2007; 4: 287-295.
165. Kang H, Kim D, Park S, Yoo J, Ryu Y,. Controlled drug release using nanoporous anodic aluminum oxide on stent. Thin Solid Films 2007; 515: 5184-5187.
166. Rajtar A KG, Yang Q, Hakimi D, Liu D, Tsui M, Lien M, Smith D, Clubb FJ, Troczynski T,. Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2006; 2: 113-115.
167. Costa JR, Abizaid A, Costa R, Feres F, Tanajura LF, Mattos LA, Staico R, Siqueira D, Sousa A, Bonan R, Sousa JE,. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. JACC-Cardiovasc Interv 2008; 1: 545-551.
168. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, Behnisch B, Schratzenstaller T, Renke-Gluszko M, Stover M,. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005; 25: 748-753.
169. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schomig A,. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006; 113: 273-279.
170. Bhargava B, Reddy NK, Karthikeyan G, Raju R, Mishra S, Singh S, Waksman R, Virmani R, Somaraju B,. A novel paclitaxel eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: Evaluation in a porcine model. Cathet Cardiovasc Interv 2006; 67: 698-702.
171. Morice M, Bestehorn H, Carrie D, Macaya C, Aengevareen W, Wijns W, Dubois C, De Winter R, Verheye S, Hoffmann S,. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2006; 2: 45-52.
172. Lansky A, Costa R, Mintz G, Tsuchiya Y, Midei M, Cox D, O'shaughnessy C, Applegate R, Cannon L, Mooney M,. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: Angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109: 1948-1954.
173. Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D, Parker S, Rowland S, Nakazawa G, Vorpahl M, Kolodgie FD, Kaluza GL, Leon MB, Virmani R,. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv 2010; 3: 257-266.
174. Spinke J, Liley M, Guder H, Angermaier L, Knoll W,. Molecular recognition at self-assembled monolayers: The construction of multicomponent multilayers. Langmuir 1993; 9: 1821-1825.
175. Sigal G, Bamdad C, Barberis A, Strominger J, Whitesides G,. A self-assembled monolayer for the binding and study of histidine-tagged proteins by surface plasmon resonance. Anal Chem 1996; 68: 490-497.
176. Fujita K, Bunjes N, Nakajima K, Hara M, Sasabe H, Knoll W,. Macrodipole interaction of helical peptides in a self-assembled monolayer on gold substrate. Langmuir 1998; 14: 6167-6172.
177. Houseman B, Gawalt E, Mrksich M,. Maleimide-functionalized self-assembled monolayers for the preparation of peptide and carbohydrate biochips. Langmuir 2003; 19: 1522-1531.
178. Huang E, Zhou F,. Studies of surface coverage and orientation of DNA molecules immobilized onto preformed alkanethiol self-assembled monolayers. Langmuir 2000; 16: 3272-3280.
179. Riepl M, Enander K, Liedberg B, Schäferling M, Kruschina M, Ortigao F,. Functionalized surfaces of mixed alkanethiols on gold as a platform for oligonucleotide microarrays. Langmuir 2002; 18: 7016-7023.
180. Herrwerth S, Rosendahl T, Feng C, Fick J, Eck W, Himmelhaus M, Dahint R, Grunze M,. Covalent coupling of antibodies to self-assembled monolayers of carboxy-functionalized poly (ethylene glycol): Protein resistance and specific binding of biomolecules. Langmuir 2003; 19: 1880-1887.
181. Kwon Y, Han Z, Karatan E, Mrksich M, Kay B,. Antibody arrays prepared by cutinase-mediated immobilization on self-assembled monolayers. Anal Chem 2004; 76: 5713-5720.
182. Gawalt E, Avaltroni M, Danahy M, Silverman B, Hanson E, Midwood K, Schwarzbauer J, Schwartz J,. Bonding organics to Ti alloys: Facilitating human osteoblast attachment and spreading on surgical implant materials. Langmuir 2003; 19: 200-204.
183. Adden N, Gamble L, Castner D, Hoffmann A, Gross G, Menzel H,. Phosphonic acid monolayers for binding of bioactive molecules to titanium surfaces. Langmuir 2006; 22: 8197-8204.
184. Mahapatro A, Johnson D, Patel D, Feldman M, Ayon A, Agrawal C,. Surface modification of functional self-assembled monolayers on 316L stainless steel via lipase catalysis. Langmuir 2006; 22: 901-905.
185. Mahapatro A, Johnson D, Patel D, Feldman M, Ayon A, Agrawal C,. Drug delivery from therapeutic self-assembled monolayers (T-SAMs) on 316L stainless steel. Curr Top Med Chem 2008; 8: 281-289.
186. Mani G, Johnson D, Marton D, Feldman M, Patel D, Ayon A, Agrawal C,. Drug delivery from gold and titanium surfaces using self-assembled monolayers. Biomaterials 2008; 29: 4561-4573.
187. Tidwell C, Ertel S, Ratner B, Tarasevich B, Atre S, Allara D,. Endothelial cell growth and protein adsorption on terminally functionalized, self-assembled monolayers of alkanethiolates on gold. Langmuir 1997; 13: 3404-3413.
188. Ulman A,. Formation and structure of self-assembled monolayers. Chem Rev 1996; 96: 1533-1554.
189. Love J, Estroff L, Kriebel J, Nuzzo R, Whitesides G,. Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 2005; 105: 1103-1170.
190. Gawalt E, Avaltroni M, Koch N, Schwartz J,. Self-assembly and bonding of alkanephosphonic acids on the native oxide surface of titanium. Langmuir 2001; 17: 5736-5738.
191. Helmy R, Fadeev A,. Self-assembled monolayers supported on TiO2: Comparison of C18H37SiX3 (X= H, Cl, OCH3), C18H37Si (CH3) 2Cl, and C18H37PO (OH) 2. Langmuir 2002; 18: 8924-8928.
192. Hofer R, Textor M, Spencer N,. Alkyl phosphate monolayers, self-assembled from aqueous solution onto metal oxide surfaces. Langmuir 2001; 17: 4014-4020.
193. Tosatti S, Michel R, Textor M, Spencer N,. Self-assembled monolayers of dodecyl and hydroxy-dodecyl phosphates on both smooth and rough titanium and titanium oxide surfaces. Langmuir 2002; 18: 3537-3548.
194. Zwahlen M, Tosatti S, Textor M, Hähner G,. Orientation in methyl-and hydroxyl-terminated self-assembled alkanephosphate monolayers on titanium oxide surfaces investigated with soft X-ray absorption. Langmuir 2002; 18: 3957-3962.
195. Silverman B, Wieghaus K, Schwartz J,. Comparative properties of siloxane vs phosphonate monolayers on a key titanium alloy. Langmuir 2005; 21: 225-228.
196. Clair S, Variola F, Kondratenko M, Jedrzejowski P, Nanci A, Rosei F, Perepichka D,. Self-assembled monolayer of alkanephosphoric acid on nanotextured Ti. J Chem Phys 2008; 128: 144705.
197. Raman A, Dubey M, Gouzman I, Gawalt E,. Formation of self-assembled monolayers of alkylphosphonic acid on the native oxide surface of SS316L. Langmuir 2006; 22: 6469-6472.
198. Kang C, Lee Y,. The surface modification of stainless steel and the correlation between the surface properties and protein adsorption. J Mater Sci Mater Med 2007; 18: 1389-1398.
199. Puleo D,. Biochemical surface modification of Co-Cr-Mo. Biomaterials 1996; 17: 217-222.
200. Quiñones R, Gawalt E,. Study of the formation of self-assembled monolayers on nitinol. Langmuir 2007; 23: 10123-10130.
201. Zorn G, Adadi R, Brener R, Yakovlev V, Gotman I, Gutmanas E, Sukenik C,. Tailoring the surface of NiTi alloy using PIRAC nitriding followed by anodization and phosphonate monolayer deposition. Chem Mater 2008; 20: 5368-5374.
202. De Palma R, Laureyn W, Frederix F, Bonroy K, Pireaux J, Borghs G, Maes G,. Formation of dense self-assembled monolayers of (n-decyl) trichlorosilanes on Ta/Ta2O5. Langmuir 2007; 23: 443-451.
203. Textor M, Ruiz L, Hofer R, Rossi A, Feldman K, Hähner G, Spencer N,. Structural chemistry of self-assembled monolayers of octadecylphosphoric acid on tantalum oxide surfaces. Langmuir 2000; 16: 3257-3271.
204. Chorny M, Fishbein I, Yellen B, Alferiev I, Bakay M, Ganta S, Adamo R, Amiji M, Friedman G, Levy R,. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci USA 2010; 107: 8346-8351.
205. Polyak B, Fishbein I, Chorny M, Alferiev I, Williams D, Yellen B, Friedman G, Levy RJ,. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steed stents. Proc Natl Acad Sci USA 2008; 105: 698-703.
206. Wykrzykowska JJ, Onuma Y, Serruys PW,. Advances in stent drug delivery: The future is in bioabsorbable stents. Expert Opin Drug Deliv 2009; 6: 113-126.
207. Ormiston J, Serruys P,. Bioabsorbable coronary stents. Circ Cardiovasc Interv 2009; 2: 255-260.
208. Tsuji T, Tamai H, Igaki K, Hsu Y-S, Kosuga K, Hata T, Okada M, Nakamura T, Fujita S,. Four-year follow-up of the biodegradable stent (Igaki-Tamai stent). Circ J 2004; 68: 135.
209. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, Dahl J, Bosserhoff AK, Michaeli W, Hanrath P, Weber C,. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004; 25: 1330-1340.
210. Okamura T, Garg S, Gutierrez-Chico JL, Shin E-S, Onuma Y, Garcia-Garcia HM, Rapoza RJ, Sudhir K, Regar E, Serruys PW,. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010; 5: 932-938.
211. Serruys PW,. BVS cohort B: Device design, 6-month update, and first report of the 12-month results. Proceedings of TCT, Washington, 21-25 September 2010.
212. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MWI, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S,. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 2008; 371: 899-907.
213. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K,. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
214. Grube E,. The REVA tyrosine-derived polycarbonate bioabsorbable stent: Final results from the RESORB first-in-man clinical trial and next generation designs. Proceedings of TCT, Washington, 12-17 October 2008.
215. Pollman MJ,. Engineering a bioresorbable stent: REVA programme update. EuroIntervention 2009; 5: F54-F57.
216. Abizaid A,. The REVA tyrosine-derived polycarbonate bioabsorbable stent: Lessons learned and future directions. Proceedings of TCT, San Francisco, 21-25 September 2009.
217. Jabara R, Pendyala L, Geva, S, Chen, J, Chronos, N, Robinson, K,. Novel fully bioabsorbale salicylate-based sirolimuseluting stent. EuroIntervention 2009; 5: F58-F64.
218. Abizaid A,. The BTI salycilate-based polyanhydride ester absorbable sirolimus-eluting stent: Update from the Whisper study. Proceedings of TCT, Washington, 12-17 October 2008.
219. Jabara R,. Poly-anhydride based on salicylic acid and adipic acid anhydride. Proceedings of Euro PCR, Barcelona, Spain, 19-22 May 2009.
220. Hermawan H, Dube D, Mantovani D,. Developments in metallic biodegradable stents. Acta Biomater 2010; 6: 1693-1697.
221. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF, Weissman N, Waksman R, Investigators PA,. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet 2007; 369: 1869-1875.
222. Waksman R,. Current state of the absorbable metallic (magnesium)stent. EuroIntervention 2009; 5: F94-F98.
223. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P,. Role of the endothelium in modulating neointimal formation-Vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004; 44: 733-739.
224. Consigny PM,. Endothelial cell seeding on prosthetic surfaces. J Long Term Eff Med Implants 2000; 10: 79-95.
225. Van der Giessen WJ, Serruys PW, Visser WJ, Verdouw PD, van Schalkwijk WP, Jongkind JF,. Endothelialization of intravascular stents. J Intervent Cardiol 1988; 1: 109-120.
226. Bailey SR, Decento YJ, Sprague E,. Endothelial seeding: Intraprocedural replacement of endothelial cells on endovascular stents. Circulation 1997; 94: I-261.
227. Shirota T, Yasui H, Shimokawa H, Matsuda T,. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials 2003; 24: 2295-2302.
228. Aoki J, Serruys PW, van Beusekom H, Ong ATL, McFadden EP, Sianos G, van der Giessen WJ, Regar E, de Feyter PJ, Davis HR, Rowland S, Kutryk MJB,. Endothelial progenitor cell capture by stents coated with antibody against CD34-The HEALING-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry. J Am Coll Cardiol 2005; 45: 1574-1579.
229. Van Belle E, Tio F, Couffinhal T, Maillard L, Passeri J, Isner J,. Stent endothelialization: Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation 1997; 95: 438-448.
230. Van Belle E, Tio F, Chen D, Maillard L, Kearney M, Isner J,. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 1997; 29: 1371-1379.
231. Shantsila E, Watson T, Lip G,. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49: 741-752.
232. Tanguay JF,. Vascular healing after stenting: The role of 17-beta-estradiol in improving re-endothelialization and reducing restenosis. Montreal, Canada: Pulsus Group Inc; 2005. pp 1025-1030.
233. Anis RR, Karsch KR,. The future of drug eluting stents. Heart 2006; 92: 585-588.
234. Cho HJ, Kim TY, Cho HJ, Park KW, Zhang SY, Kim JH, Kim SH, Hahn JY, Kang HJ, Park YB, Kim HS,. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare-metal versus paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48: 366-374.
235. Pelisek J, Fuchs AT, Kuehnl A, Tian W, Kuhlmann MT, Rolland PH, Choukri M, Gaedtke L, Nikol S,. C-Type natriuretic peptide for reduction of restenosis: Gene transfer is superior over single peptide administration. J Gene Med 2006; 8: 835-844.
236. Patel H, Su S, Patterson C, Nguyen K,. A combined strategy to reduce restenosis for vascular tissue engineering applications. Biotechnol Prog 2006; 22: 38-44.
237. Garg S, Duckers HJ, Serruys PW,. Endothelial progenitor cell capture stents: Will this technology find its niche in contemporary practice? Eur Heart J 2010; 31: 1032-1035.
238. Duckers H, Silber S, De Winter R, Heijer P, Rensing B, Rau M, Mudra H, Benit E, Verheye S, Wijns W,. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: Evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 2007; 3: 67-75.
239. Duckers H, Soullie T, Den heijer P, Rensing B, De Winter R, Rau M, Mudra H, Silber S, Benit E, Velheye S,. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: Final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroIntervention 2007; 3: 350-358.
240. Co M, Tay E, Chi Hang L, Kian K, Low A, Lim J,. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate-to long-term clinical follow-up. Am Heart J 2008; 155: 128-132.
241. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, Seitz B, Kapurniotu A, Kwok C, Dewor M, Bosserhoff AK, Bernhagen J, Hanrath P, Hofmann R, Weber C,. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol 2006; 47: 1786-1795.
242. Stefanadis C, Toutouzas K, Stefanadi E, Kolodgie F, Virmani R, Kipshidze N,. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: Angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 2006; 47: 7-10.
243. Nakazawa G, Granada J, Alviar C, Tellez A, Kaluza G, Guilhermier M, Parker S, Rowland S, Kolodgie F, Leon M,. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Interv 2010; 3: 68-75.
244. Palmaz JC, Benson A, Sprague EA,. Influence of surface topography on endothelialization of intravascular metallic material. J Vasc Interv Radiol 1999; 10: 439-444.
245. Lu J, Rao M, MacDonald N, Khang D, Webster T,. Improved endothelial cell adhesion and proliferation on patterned titanium surfaces with rationally designed, micrometer to nanometer features. Acta Biomater 2008; 4: 192-201.
246. Ranjan A, Webster TJ,. Increased endothelial cell adhesion and elongation on micron-patterned nano-rough poly(dimethylsiloxane) films. Nanotechnology 2009; 20: 305102.
247. Hwang SY, Kwon KW, Jang KJ, Park MC, Lee JS, Suh KY,. Adhesion assays of endothelial cells on nanopatterned surfaces within a microfluidic channel. Anal Chem 2010; 82: 3016-3022.
248. Bettinger C, Zhang Z, Gerecht S, Borenstein JT, Langer R,. Enhancement of in vitro capillary tube formation by substrate nanotopography. Adv Mater 2008; 20: 99-103.
249. Berry C, McCloy D, Affrossman S,. Endothelial cell response to narrow diameter nylon tubes exhibiting internal nanotopography. Curr Nanosci 2008; 4: 219-223.
250. Hsu SH, Tang CM, Lin CC,. Biocompatibility of poly(epsilon-caprolactone)/ poly(ethylene glycol) diblock copolymers with nanophase separation. Biomaterials 2004; 25: 5593-5601.
251. Dalby MJ, Riehle MO, Johnstone H, Affrossman S, Curtis ASG,. In vitro reaction of endothelial cells to polymer demixed nanotopography. Biomaterials 2002; 23: 2945-2954.
252. Buttiglieri S, Pasqui D, Migliori M, Johnstone H, Affrossman S, Sereni L, Wratten ML, Barbucci R, Tetta C, Camussi G,. Endothelization and adherence of leucocytes to nanostructured surfaces. Biomaterials 2003; 24: 2731-2738.
253. Barbucci R, Pasqui D, Wirsen A, Affrossman S, Curtis A, Tetta C,. Micro and nano-structured surfaces. J Mater Sci Mater Med 2003; 14: 721-725.
254. Kim P, Kim DH, Kim B, Choi SK, Lee SH, Khademhosseini A, Langer R, Suh KY,. Fabrication of nanostructures of polyethylene glycol for applications to protein adsorption and cell adhesion. Nanotechnology 2005; 16: 2420-2426.
255. Zawislak JD, Kolasinski KW, Helmke BP,. Development of endothelial cells on pillar-covered silicon. Phys Status Solidi A-Appl Mater Sci 2009; 206: 1356-1360.
256. Choudhary S, Berhe M, Haberstroh KM, Webster TJ,. Increased endothelial and vascular smooth muscle cell adhesion on nanostructured titanium and CoCrMo. Int J Nanomed 2006; 1: 41-49.
257. Choudhary S, Haberstroh KM, Webster TJ,. Enhanced functions of vascular cells on nanostructured Ti for improved stent applications. Tissue Eng 2007; 13: 1421-1430.
258. Khang D, Lu J, Yao C, Haberstroh KM, Webster TJ,. The role of nanometer and sub-micron surface features on vascular and bone cell adhesion on titanium. Biomaterials 2008; 29: 970-983.
259. Peng L, Eltgroth ML, LaTempa TJ, Grimes CA, Desai TA,. The effect of TiO2 nanotubes on endothelial function and smooth muscle proliferation. Biomaterials 2009; 30: 1268-1272.
260. Samaroo HD, Lu J, Webster TJ,. Enhanced endothelial cell density on NiTi surfaces with sub-macron to nanometer roughness. Int J Nanomed 2008; 3: 75-82.
261. Carpenter J, Khang D, Webster TJ,. Nanometer polymer surface features: The influence on surface energy, protein adsorption and endothelial cell adhesion. Nanotechnology 2008; 19: 505103.
262. Serrano MC, Portoles MT, Vallet-Regi M, Izquierdo I, Galletti L, Comas JV, Pagani R,. Vascular endothelial and smooth muscle cell culture on NaOH-treated poly (epsilon-caprolactone) films: A preliminary study for vascular graft development. Macromol Biosci 2005; 5: 415-423.
263. Miller DC, Thapa A, Haberstroh KM, Webster TJ,. Endothelial and vascular smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface features. Biomaterials 2004; 25: 53-61.
264. Lord MS, Cousins BG, Doherty PJ, Whitelock JM, Simmons A, Williams RL, Milthorpe BK,. The effect of silica nanoparticulate coatings on serum protein adsorption and cellular response. Biomaterials 2006; 27: 4856-4862.
265. Sarkar S, Dadhania M, Rourke P, Desai TA, Wong JY,. Vascular tissue engineering: Microtextured scaffold templates to control organization of vascular smooth muscle cells and extracellular matrix. Acta Biomater 2005; 1: 93-100.
266. Glawe JD, Hill JB, Mills DK, McShane MJ,. Influence of channel width on alignment of smooth muscle cells by high-aspect-ratio microfabricated elastomeric cell culture scaffolds. J Biomed Mater Res Part A 2005; 75A: 106-114.
267. Houtchens GR, Foster MD, Desai TA, Morgan EF, Wong JY,. Combined effects of microtopography and cyclic strain on vascular smooth muscle cell orientation. J Biomech 2008; 41: 762-769.
268. Yim EKF, Reano RM, Pang SW, Yee AF, Chen CS, Leong KW,. Nanopattern-induced changes in morphology and motility of smooth muscle cells. Biomaterials 2005; 26: 5405-5413.
269. Nguyen KT, Shukla KP, Moctezuma M, Tang LP,. Cellular and molecular responses of smooth muscle cells to surface nanotopography. J Nanosci Nanotechnol 2007; 7: 2823-2832.
270. Richert L, Vetrone F, Yi JH, Zalzal SF, Wuest JD, Rosei F, Nanci A,. Surface nanopatterning to control cell growth. Adv Mater 2008; 20: 1488-1492.
271. Gao JM, Niklason L, Langer R,. Surface hydrolysis of poly(glycolic acid) meshes increases the seeding density of vascular smooth muscle cells. J Biomed Mater Res 1998; 42: 417-424.
272. Thapa A, Miller DC, Webster TJ, Haberstroh KM,. Nano-structured polymers enhance bladder smooth muscle cell function. Biomaterials 2003; 24: 2915-2926.
273. Walboomers XF, Croes HJE, Ginsel LA, Jansen JA,. Growth behavior of fibroblasts on microgrooved polystyrene. Biomaterials 1998; 19: 1861-1868.
274. Walboomers XF, Croes HJE, Ginsel LA, Jansen JA,. Contact guidance of rat fibroblasts on various implant materials. J Biomed Mater Res 1999; 47: 204-212.
275. Walboomers XF, Monaghan W, Curtis ASG, Jansen JA,. Attachment of fibroblasts on smooth and microgrooved polystyrene. J Biomed Mater Res 1999; 46: 212-220.
276. Walboomers XF, Ginsel LA, Jansen JA,. Early spreading events of fibroblasts on microgrooved substrates. J Biomed Mater Res 2000; 51: 529-534.
277. Meyle J, Gultig K, Nisch W,. Variation in contact guidance by human-cells on a microstructured surface. J Biomed Mater Res 1995; 29: 81-88.
278. Lee SW, Kim SY, Rhyu IC, Chung WY, Leesungbok R, Lee KW,. Influence of microgroove dimension on cell behavior of human gingival fibroblasts cultured on titanium substrata. Clin Oral Implants Res 2009; 20: 56-66.
279. Chou LS, Firth JD, Uitto VJ, Brunette DM,. Substratum surface-Topography alters cell-shape and regulates fribronectin messenger-RNA level, messenger-RNA stability, secretion and assembly in human fibroblasts. J Cell Sci 1995; 108: 1563-1573.
280. Biela SA, Su Y, Spatz JP, Kemkemer R,. Different sensitivity of human endothelial cells, smooth muscle cells and fibroblasts to topography in the nano-micro range. Acta Biomater 2009; 5: 2460-2466.
281. Loesberg WA, te Riet J, van Delft F, Schon P, Figdor CG, Speller S, van Loon J, Walboomers XF, Jansen JA,. The threshold at which substrate nanogroove dimensions may influence fibroblast alignment and adhesion. Biomaterials 2007; 28: 3944-3951.
282. Sun F, Casse D, van Kan JA, Ge RW, Watt F,. Geometric control of fibroblast growth on proton beam-micromachined scaffolds. Tissue Eng 2004; 10: 267-272.
283. Berry CC, Dalby MJ, McCloy D, Affrossman S,. The fibroblast response to tubes exhibiting internal nanotopography. Biomaterials 2005; 26: 4985-4992.
284. Dalby MJ, Riehle MO, Johnstone HJH, Affrossman S, Curtis ASG,. Polymer-demixed nanotopography: Control of fibroblast spreading and proliferation. Tissue Eng 2002; 8: 1099-1108.
285. Dalby MJ, Giannaras D, Riehle MO, Gadegaard N, Affrossman S, Curtis ASG,. Rapid fibroblast adhesion to 27 nm high polymer demixed nano-topography. Biomaterials 2004; 25: 77-83.
286. Dalby M, Riehle M, Johnstone H, Affrossman S, Curtis A,. Polymer-demixed nanotopography: Control of fibroblast spreading and proliferation. Tissue Eng 2002; 8: 1099-1108.
287. Dalby MJ, Riehle MO, Johnstone HJH, Affrossman S, Curtis ASG,. Nonadhesive nanotopography: Fibroblast response to poly(n-butyl methacrylate)-poly(styrene) demixed surface features. J Biomed Mater Res Part A 2003; 67A: 1025-1032.
288. Dalby MJ, Gadegaard N, Riehle MO, Wilkinson CDW, Curtis ASG,. Investigating filopodia sensing using arrays of defined nano-pits down to 35 nm diameter in size. Int J Biochem Cell Biol 2004; 36: 2005-2015.
289. Dalby MJ, Gadegaard N, Wilkinson CDW,. The response of fibroblasts to hexagonal nanotopography fabricated by electron beam lithography. J Biomed Mater Res Part A 2008; 84A: 973-979.
290. Green AM, Jansen JA, Vanderwaerden J, Vonrecum AF,. Fibroblast response to microtextured silicone surfaces: Texture orientation into or out of the surface. J Biomed Mater Res 1994; 28: 647-653.
291. Milner KR, Siedlecki CA,. Submicron poly(L -lactic acid) pillars affect fibroblast adhesion and proliferation. J Biomed Mater Res Part A 2007; 82A: 80-91.
292. Hunt JA, Williams RL, Tavakoli SM, Riches ST,. Laser surface modification of polymers to improve biocompatibility. J Mater Sci Mater Med 1995; 6: 813-817.
293. Dalby MJ, Berry CC, Riehle MO, Sutherland DS, Agheli H, Curtis ASG,. Attempted endocytosis of nano-environment produced by colloidal lithography by human fibroblasts. Exp Cell Res 2004; 295: 387-394.
294. Choi CH, Hagvall SH, Wu BM, Dunn JCY, Beygui RE, Kim CJ,. Cell interaction with three-dimensional sharp-tip nanotopography. Biomaterials 2007; 28: 1672-1679.
295. Choi CH, Heydarkhan-Hagvall S, Wu BM, Dunn JCY, Beygui RE, Kim CJ,. Cell growth as a sheet on three-dimensional sharp-tip nanostructures. J Biomed Mater Res Part A 2009; 89A: 804-817.
296. Vance RJ, Miller DC, Thapa A, Haberstroh KM, Webster TJ,. Decreased fibroblast cell density on chemically degraded poly-lactic-co-glycolic acid, polyurethane, and polycaprolactone. Biomaterials 2004; 25: 2095-2103.
297. Cousins BG, Doherty PJ, Williams RL, Fink J, Garvey MJ,. The effect of silica nanoparticulate coatings on cellular response. J Mater Sci Mater Med 2004; 15: 355-359.
298. Flemming RG, Murphy CJ, Abrams GA, Goodman SL, Nealey PF,. Effects of synthetic micro- and nano-structured surfaces on cell behavior. Biomaterials 1999; 20: 573-588.
299. Norman J, Desai T,. Methods for fabrication of nanoscale topography for tissue engineering scaffolds. Ann Biomed Eng 2006; 34: 89-101.
300. Tseng AA, Notargiacomo A,. Nanoscale fabrication by nonconventional approaches. J Nanosci Nanotechnol 2005; 5: 683-702.
301. Dolatshahi-Pirouz A, Hovgaard MB, Rechendorff K, Chevallier J, Foss M, Besenbacher F,. Scaling behavior of the surface roughness of platinum films grown by oblique angle deposition. Phys Rev B 2008; 77:Article number 115427.
302. Buzea C, Beydaghyan G, Elliott C, Robbie K,. Control of power law scaling in the growth of silicon nanocolumn pseudo-regular arrays deposited by glancing angle deposition. Nanotechnology 2005; 16: 1986-1992.
303. LaFratta CN, Li LJ, Fourkas JT,. Soft-lithographic replication of 3D microstructures with closed loops. Proc Natl Acad Sci USA 2006; 103: 8589-8594.
304. Pikulin A, Bityurin N,. Spatial resolution in polymerization of sample features at nanoscale. Phys Rev B 2007; 75:DOI 10.1103.
305. Seunarine K, Meredith DO, Riehle MO, Wilkinson CDW, Gadegaard N,. Biodegradable polymer tubes with litho graphically controlled 3D micro- and nanotopography. Microelectron Eng 2008; 85: 1350-1354.
306. In HJ, Kumar S, Shao-Horn Y, Barbastathis G,. Origami fabrication of nanostructured, three-dimensional devices: Electrochemical capacitors with carbon electrodes. Appl Phys Lett 2006; 88:DOI 10.1063/1.2177639.
307. Fuss C SE, Bailey SR, Palmaz JC,. Surface micro grooves (MG) improve endothelialization rate in vitro and in vivo. Am J Cardiol 2001; 37: 70A.
308. Dalby MJ, Riehle MO, Johnstone H, Affrossman S, Curtis ASG,. Investigating the limits of filopodial sensing: A brief report using SEM to image the interaction between 10 nm high nano-topography and fibroblast filopodia. Cell Biol Int 2004; 28: 229-236.
309. Milner KR, Siedlecki CA,. Fibroblast response is enhanced by poly(L -lactic acid) nanotopography edge density and proximity. Int J Nanomed 2007; 2: 201-211.
310. Dalby MJ, Riehle MO, Sutherland DS, Agheli H, Curtis ASG,. Use of nanotopography to study mechanotransduction in fibroblasts-Methods and perspectives. Eur J Cell Biol 2004; 83: 159-169.
311. Dalby MJ, Biggs MJP, Gadegaard N, Kalna G, Wilkinson CDW, Curtis ASG,. Nanotopographical stimulation of mechanotransduction and changes in interphase centromere positioning. J Cell Biochem 2007; 100: 326-338.